Sirtinol
CAS: 410536-97-9
Ref. 3D-FS153609
| 1g | Discontinued | ||
| 2g | Discontinued | ||
| 100mg | Discontinued | ||
| 250mg | Discontinued | ||
| 500mg | Discontinued |
Product Information
- 2-[[(2-Hydroxy-1-naphthalenyl)methylene]amino]-N-(1-phenylethyl)benzamide
- 2-{[(2-oxonaphthalen-1(2H)-ylidene)methyl]amino}-N-[(1R)-1-phenylethyl]benzamide
- Benzamide, 2-[[(2-hydroxy-1-naphthalenyl)methylene]amino]-N-(1-phenylethyl)-
- S 2804
Sirtinol is an experimental drug that has been shown to have antioxidative properties and is being investigated for the treatment of autoimmune diseases and cancer. Sirtinol increases mitochondrial membrane potential, which leads to increased energy metabolism in cells. It also has anti-inflammatory properties, which may be due to its ability to inhibit NF-κB activation. Sirtinol has been shown to reduce cell viability in cancer cells, and is a potent chemotherapeutic agent that can induce autophagy and apoptosis.
!--[if !supportLists]-->· !--[endif]-->Sirtinol has been shown to inhibit the proliferation of breast cancer cells by reducing levels of cyclin D1.!--[if !supportLists]-->· !--[endif]-->It also reduces lipid peroxidation in red blood cells.!--[if !supportLists]-->· !--[endif]-->In vivo studies have shown that sirtinol can protect
